BridgeMD
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
EU CTIS ID: 2023-503714-77-00
What this study is testing
Evaluate the efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for advanced NSCLC patients with KRAS G12C mutation.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation. a. Cohort A* (closed): squamous or nonsquamous histology b. Cohorts C and E*: nonsquamous histology only
You likely can't join if
- Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy (CIT in Cohorts A and E only), any therapy targeting KRAS G12C mutation (eg, sotorasib) , or received maintenance therapy, eg, pembrolizumab and/or pemetrexed following completion 4-6 cycles of a platinum-based regimen administered in the first-line setting (Cohort C only)
- Radiation to the lung > 30 Gy within 6 months prior to first dose of study treatment.
- Active brain metastases.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.